Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited

Life Sciences [q-bio] Microbiology and Parasitology Bacteriology Life Sciences [q-bio] Microbiology and Parasitology Virology Life Sciences [q-bio] Microbiology and Parasitology Parasitology Life Sciences [q-bio] Human health and pathology Cardiology and cardiovascular system Life Sciences [q-bio] Human health and pathology Emerging diseases Life Sciences [q-bio] Human health and pathology Infectious diseases

Isabelle COMBE : Connect in order to contact the contributor

https://hal-amu.archives-ouvertes.fr/hal-03215698

Submitted on : Monday, May 3, 2021-2:56:54 PM

Last modification on : Friday, March 24, 2023-2:53:21 PM

Dates and versions

hal-03215698 , version 1 (03-05-2021)

Identifiers

HAL Id : hal-03215698 , version 1
DOI : 10.1016/j.ijantimicag.2020.106243
PUBMEDCENTRAL : PMC7779265

Cite

Philippe Gautret, Jean-Christophe Lagier, Stéphane Honoré, van Thuan Hoang, Philippe Colson, et al.. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. International Journal of Antimicrobial Agents, 2021, 57 (1), pp.106243. ⟨10.1016/j.ijantimicag.2020.106243⟩. ⟨hal-03215698⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

CNRS UNIV-AMU INCIAM

14 View

0 Download